A detailed history of Stephens Consulting, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 21 shares of REGN stock, worth $15,636. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21
Previous 25 16.0%
Holding current value
$15,636
Previous $26.3 Million 15.98%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$1024.09 - $1201.76 $4,096 - $4,807
-4 Reduced 16.0%
21 $22.1 Million
Q2 2024

Jul 29, 2024

BUY
$883.2 - $1071.19 $22,080 - $26,779
25 New
25 $26.3 Million
Q3 2023

Oct 25, 2023

BUY
$692.45 - $844.37 $69,245 - $84,437
100 New
100 $82.3 Million
Q4 2022

Jan 19, 2023

SELL
$705.89 - $766.39 $20,470 - $22,225
-29 Closed
0 $0
Q4 2021

Jan 19, 2023

BUY
$543.48 - $670.97 $15,760 - $19,458
29 New
29 $18.3 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.8B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Stephens Consulting, LLC Portfolio

Follow Stephens Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.